About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals is a publicly listed company based in Vancouver (Canada) founded in 2012 by James Helliwell. Sustained-release drug delivery platform for osteoarthritis therapies is developed. Eupraxia Pharmaceuticals has raised $2.44 million across 10 funding rounds from investors including SVB and National Research Council Canada. Its chief executive, as recorded, is James Helliwell. Its focus areas include HealthTech, Veterinary HealthTech, Biopharmaceuticals and Companion Animals.
Company details
Eupraxia Pharmaceuticals is a pharmaceutical company that has a proprietary drug delivery platform. The technology encapsulates pharmaceutical microparticles in a customizable polymer shell that can extend drug release from days to months. The company works on the existing drugs and uses its injectable drug delivery platform for targeted therapies. It also has preclinical and development phase candidates for chronic pain, anesthesia, diabetic macular edema, and infections. The companys lead product candidate, EP-104IAR (phase I clinical trial) is a sustained-release product of the anti-inflammatory, fluticasone propionate for pain relief for patients with osteoarthritis. It also has a phase 1 candidate for veterinary health. In 2016, the company has entered into a license agreement with Auritec under which Eupraxia licensed the Plexis platform technology and intellectual property rights from Auritec for the sustained delivery of corticosteroids.
- Headquarters Vancouver, Canada
- Founders James Helliwell
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website eupraxiapharma.com
- Social LinkedIn X
- Legal Name Eupraxia Pharmaceuticals, Inc.
- Net Profit-$39.37 M (USD)-54.28as on Dec 31, 2025
- EBITDA-$38.98 M (USD)-45.19as on Dec 31, 2025
- Total Equity Funding$2.44M (USD)
in 10 rounds
- Latest Funding Round$32M (USD), Post-IPO
Oct 2024
- InvestorsSVB
& 1 more
Funding Insights of Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals has successfully raised a total of $2.44M across 10 strategic funding rounds. The most recent funding activity was a Post-IPO round of $32 million completed in October 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.44M
- Total Rounds 10
- Last Round Post-IPO — $32M
- First Round $10,139
(Aug 2012)
- Investors Count 2
All 10 funding rounds of Eupraxia Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2024 | $32M | Post-IPO | – | – | – |
| Aug 2023 | $16.47M | Post-IPO | – | – | – |
| Nov 2021 | $700,000 | Grant | – | – | |
| Jun 2021 | $8.02M | Post-IPO | – | – | |
| Apr 2017 | $1.97M | Seed | – | – | – |
| Apr 2016 | $37,951 | Seed | – | – | – |
| Sep 2013 | $24,277 | Seed | – | – | – |
| Jul 2013 | $23,782 | Seed | – | – | – |
| Dec 2012 | $376,848 | Seed | – | – | – |
| Aug 2012 | $10,139 | Seed | – | – | – |
2 investors in total: 2 institutional.
Investors in Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include SVB and National Research Council Canada.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Scientific and technological research is conducted for Canada's benefit. | 1916 | nrc.canada.ca | Ottawa, Canada | |
Banking services are provided to innovative companies, investors, and individuals. | 1983 | svb.com | Santa Clara, United States |
Investor details for Eupraxia Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Eupraxia Pharmaceuticals
1 people are tracked at Eupraxia Pharmaceuticals (1 in leadership).
| Name | Role | Group |
|---|---|---|
James Helliwell | Founder & CEO | Leadership |
Complete people profiles for Eupraxia Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals is a publicly listed company on the TSX with ticker symbol EPRX in Canada, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date03 Aug 2021
- Listed onNASDAQ: EPRX
- Listed entityEupraxia Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINCA29842P1053
- Share price9.59 CAD (-9.78% on the day) · 2026-10-13
- Market capitalisation632,044,606.00 CAD
- EPS (diluted, trailing year)-1.36 CAD
- Volume (last session)157,322
Financials of Eupraxia Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -53.9M CAD | -53.4M CAD | |
| 2024 | -34.9M CAD | -36.8M CAD | |
| 2023 | -38.1M CAD | -37.7M CAD | |
| 2022 | -23.3M CAD | -23.4M CAD | |
| 2021 | -23.0M CAD | -18.4M CAD |
Detailed financial statements for Eupraxia Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Eupraxia Pharmaceuticals
4 dated milestones of Eupraxia Pharmaceuticals across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Eupraxia Pharmaceuticals is founded.
- Funding First funding round of $10K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $32.0M.
Web traffic of Eupraxia Pharmaceuticals
The website of Eupraxia Pharmaceuticals (eupraxiapharma.com) receives about 2.9K visits a month.
- Monthly visits2.9K
▲ 21.2% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Eupraxia Pharmaceuticals
Complete news archive for Eupraxia Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals was founded in 2012.
Eupraxia Pharmaceuticals is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.
James Helliwell is the CEO of Eupraxia Pharmaceuticals, as recorded in our data. They have also founded this company.
Eupraxia Pharmaceuticals is a funded company, having raised a total of $2.44M across 10 funding rounds to date. The company's 1st funding round was a Seed of $10.14K, raised on Aug 2012.
Eupraxia Pharmaceuticals is a pharmaceutical company that has a proprietary drug delivery platform. The technology encapsulates pharmaceutical microparticles in a customizable polymer shell that can extend drug release from days to months. The company works on the existing drugs and uses its injectable drug delivery platform for targeted therapies. It also has preclinical and development phase candidates for chronic pain, anesthesia, diabetic macular edema, and infections. The companys lead product candidate, EP-104IAR (phase I clinical trial) is a sustained-release product of the anti-inflammatory, fluticasone propionate for pain relief for patients with osteoarthritis. It also has a phase 1 candidate for veterinary health. In 2016, the company has entered into a license agreement with Auritec under which Eupraxia licensed the Plexis platform technology and intellectual property rights from Auritec for the sustained delivery of corticosteroids.
Yes, Eupraxia Pharmaceuticals is publicly traded on TSX under the ticker symbol EPRX.
Eupraxia Pharmaceuticals has 2 investors. Key investors include SVB, and National Research Council Canada.